|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||21.08 - 21.22|
|52 Week Range||16.87 - 25.77|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.53|
|Expense Ratio (net)||0.79%|
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
While we can research the family tree for these health issues, it’s been difficult to know for sure what could happen — until now. Because of breakthroughs in human genome mapping, we can now get a clear line of sight on what diseases are coming our way — and the insights are only getting better.
A version of this article was published in the December 2018 issue of Morningstar ETFInvestor. Download a complimentary copy of Morningstar ETFInvestor by visiting the website. Simple, compelling stories tap into our emotions, hijack our ability to think rationally, and persuade us to pursue investments that are unlikely to perform well. The South Sea Company of early 18th century England exemplifies how a well-spun narrative can cause investors to ignore facts and disrupt their ability to make sound investment decisions.
After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed threats of global slowdown.
Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after FDA Commissioner Scott Gottlieb unexpectedly resigned, ...
A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...
The Loncar China BioPharma ETF (NASDAQ: CHNA) debuted Wednesday, marking the second ETF from Loncar Investments. CHNA follows the Loncar China BioPharma Index, which was developed by Loncar founder Brad Loncar. “China aims to become a leader in global medicine,” Loncar said in a statement.
Today, the Loncar China BioPharma ETF (Nasdaq:CHNA) begins trading on the Nasdaq in the United States. The CHNA ETF seeks to give investors access to China’s rapidly-developing biopharmaceutical industry. It is based on the Loncar China BioPharma Index, an innovative index developed by biotechnology investor Brad Loncar.
As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.
The healthcare sector is the second-largest sector exposure in the S&P 500. This prominence is reflected in the world of exchange-traded funds (ETFs), where there are dozens of healthcare ETFs.